Target Price | $60.64 |
Price | $49.01 |
Potential |
23.72%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2025 .
The average Rhythm Pharmaceuticals, Inc. target price is $60.64.
This is
23.72%
register free of charge
$77.00
57.11%
register free of charge
$52.00
6.10%
register free of charge
|
|
A rating was issued by 11 analysts: 10 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2025 of
23.72%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 77.43 | 123.15 |
227.54% | 59.05% | |
EBITDA Margin | -235.83% | -223.88% |
68.64% | 5.07% | |
Net Margin | -252.51% | -218.80% |
71.93% | 13.35% |
11 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2024 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2024. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.20 | -4.41 |
8.05% | 37.81% | |
P/E | negative | |
EV/Sales | 23.79 |
3 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Rhythm Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.